Vumerity Recommended for EU Approval as RRMS Treatment

Vumerity Recommended for EU Approval as RRMS Treatment

306502

Vumerity Recommended for EU Approval as RRMS Treatment

A committee of the European Medicines Agency is recommending that Vumerity (diroximel fumarate) be approved as an oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS) in the European Union. The opinion, from the agency’s Committee for Medicinal Products for Human Use (CHMP), will now be sent to the European Commission, which will issue a final decision and has historically followed the committee’s recommendations. “Today’s CHMP opinion is a crucial step forward in providing an oral…

You must be logged in to read/download the full post.